Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

BACKGROUND: This phase 1b study evaluated an enteric-coated tablet (ECT) formulation of the investigational Aurora A kinase inhibitor, alisertib (MLN8237). METHODS: Patients with advanced, non-hematologic malignancies received oral alisertib ECT for 7 days BID followed by 14 days treatment-free (21-...

Cur síos iomlán

Na minha lista:
Sonraí Bibleagrafaíochta
Foilsithe in:Invest New Drugs
Main Authors: Falchook, Gerald, Kurzrock, Razelle, Gouw, Launce, Hong, David, McGregor, Kimberly A., Zhou, Xiaofei, Shi, Hongliang, Fingert, Howard, Sharma, Sunil
Formáid: Artigo
Teanga:Inglês
Foilsithe: 2014
Ábhair:
Article
Rochtain Ar Líne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4229392/
https://ncbi.nlm.nih.gov/pubmed/24879333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0121-6
Clibeanna: Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!

Míreanna Comhchosúla